{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:34:44Z","timestamp":1780043684356,"version":"3.53.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100004328","name":"Genentech","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100004328","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pulm Med"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>Pirfenidone and nintedanib are antifibrotic therapies which slow disease progression in idiopathic pulmonary fibrosis (IPF), an irreversible, progressive lung disease with poor prognosis. We compared adherence, persistence, and healthcare costs between patients initiating one of the two therapies.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>We used the IBM Watson Health Commercial and Medicare Supplemental claims databases to select patients with IPF with \u22651 pharmacy claim for pirfenidone or nintedanib between 10\/1\/2014 and 6\/30\/2018. Adherence (proportion of days covered \u22650.80) and persistence (time to a gap of \u226560\u2009days without medication or switch to the other antifibrotic medication) based on the days\u2019 supply and service date fields on claims were measured over a variable-length follow-up period. Healthcare costs, all-cause and respiratory-related, were measured over the persistent period and a fixed 12-month follow-up period. Inverse probability of treatment weights were applied to models comparing adherence, persistence, and costs between the two cohorts.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Overall, 799 pirfenidone patients and 656 nintedanib patients were identified. Similar proportions of patients were adherent in both cohorts (pirfenidone\u2009=\u200949% vs. nintedanib\u2009=\u200951%) and there was no significant difference in the odds of being adherent after weighting (odds ratio\u2009=\u20091.1, <jats:italic>p<\/jats:italic>\u2009=\u20090.513). The proportions of patients who discontinued\/switched were also similar (pirfenidone\u2009=\u200941% vs. nintedanib 43%); however, in a weighted model, the hazards of discontinuation\/switching was lower for the pirfenidone cohort (hazard ratio\u2009=\u20090.8, <jats:italic>p<\/jats:italic>\u2009=\u20090.032). While patients were persistent on therapy, weighted all-cause healthcare costs were comparable (pirfenidone\u2009=\u2009$11,272 vs. nintedanib\u2009=\u2009$11,987 per-patient per-month; <jats:italic>p<\/jats:italic>\u2009=\u20090.115), but weighted respiratory-related costs were significantly lower for the pirfenidone cohort ($9015 vs. $10,167 per-patient per-month, <jats:italic>p\u2009&lt;<\/jats:italic>\u00a00.001). Weighted annual total all-cause and respiratory-related healthcare costs were comparable between cohorts over the fixed 12-month follow-up period, but the pirfenidone cohort had significantly lower weighted annual mean antifibrotic drug costs than the nintedanib cohort ($68,850 vs. $77,033, <jats:italic>p<\/jats:italic>\u2009=\u20090.007).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusions<\/jats:title>\n<jats:p>Pirfenidone use was associated with longer time to discontinuation\/switch, lower antifibrotic drug costs, and lower respiratory-related total costs compared to nintedanib use.<\/jats:p>\n<\/jats:sec>","DOI":"10.1186\/s12890-020-01224-5","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T09:02:51Z","timestamp":1594458171000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":28,"title":["Treatment patterns, healthcare resource utilization, and costs among patients with idiopathic pulmonary fibrosis treated with antifibrotic medications in US-based commercial and Medicare Supplemental claims databases: a retrospective cohort study"],"prefix":"10.1186","volume":"20","author":[{"given":"Mitra","family":"Corral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kathryn","family":"DeYoung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amanda M.","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"issue":"9807","key":"1224_CR1","doi-asserted-by":"publisher","first-page":"1949","DOI":"10.1016\/S0140-6736(11)60052-4","volume":"378","author":"TE King Jr","year":"2011","unstructured":"King TE Jr, Pardo A, Selman M. Idiopathic pulmonary fibrosis. Lancet. 2011;378(9807):1949\u201361.","journal-title":"Lancet"},{"issue":"2","key":"1224_CR2","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","volume":"192","author":"G Raghu","year":"2015","unstructured":"Raghu G, Rochwerg B, Zhang Y, Garcia CA, Azuma A, Behr J, et al. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline. Am J Respir Crit Care Med. 2015;192(2):e3\u201319.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1224_CR3","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1183\/13993003.01653-2015","volume":"48","author":"G Raghu","year":"2016","unstructured":"Raghu G, Chen SY, Hou Q, Yeh WS, Collard HR. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults 18-64 years old. Eur Respir J. 2016;48(1):179\u201386.","journal-title":"Eur Respir J"},{"issue":"7","key":"1224_CR4","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1164\/rccm.200602-163OC","volume":"174","author":"G Raghu","year":"2006","unstructured":"Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2006;174(7):810\u20136.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"1224_CR5","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1164\/ajrccm.150.4.7921471","volume":"150","author":"DB Coultas","year":"1994","unstructured":"Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med. 1994;150(4):967\u201372.","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"1224_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.ccm.2011.12.001","volume":"33","author":"AL Olson","year":"2012","unstructured":"Olson AL, Swigris JJ. Idiopathic pulmonary fibrosis: diagnosis and epidemiology. Clin Chest Med. 2012;33(1):41\u201350.","journal-title":"Clin Chest Med"},{"issue":"7","key":"1224_CR7","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1016\/S2213-2600(14)70101-8","volume":"2","author":"G Raghu","year":"2014","unstructured":"Raghu G, Chen SY, Yeh WS, Maroni B, Li Q, Lee YC, et al. Idiopathic pulmonary fibrosis in US Medicare beneficiaries aged 65 years and older: incidence, prevalence, and survival, 2001-11. Lancet Respir Med. 2014;2(7):566\u201372.","journal-title":"Lancet Respir Med"},{"issue":"4","key":"1224_CR8","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1183\/09031936.00155108","volume":"35","author":"CJ Zappala","year":"2010","unstructured":"Zappala CJ, Latsi PI, Nicholson AG, Colby TV, Cramer D, Renzoni EA, et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J. 2010;35(4):830\u20136.","journal-title":"Eur Respir J"},{"key":"1224_CR9","volume-title":"Esbriet (pirfenidone) [US package insert] [Internet]","author":"Genentech Inc","year":"2019","unstructured":"Genentech Inc. Esbriet (pirfenidone) [US package insert] [Internet]. South San Francisco: Genentech, Inc; 2019. [updated 2019 Jul; cited 2019 Dec 10]. Available from: https:\/\/www.gene.com\/download\/pdf\/esbriet_prescribing.pdf."},{"key":"1224_CR10","volume-title":"Ofev (nintedanib) [package insert] [Internet]","author":"Boehringer Ingelheim Pharmaceuticals","year":"2019","unstructured":"Boehringer Ingelheim Pharmaceuticals. Ofev (nintedanib) [package insert] [Internet]. Ridgefield: Boehringer Ingelheim Pharmaceuticals; 2019. [updated 2019 Sep; cited 2019 Dec 10]. Available from: https:\/\/docs.boehringer-ingelheim.com\/Prescribing%20Information\/PIs\/Ofev\/ofev.pdf."},{"issue":"22","key":"1224_CR11","doi-asserted-by":"publisher","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","volume":"370","author":"TE King Jr","year":"2014","unstructured":"King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083\u201392.","journal-title":"N Engl J Med"},{"issue":"9779","key":"1224_CR12","doi-asserted-by":"publisher","first-page":"1760","DOI":"10.1016\/S0140-6736(11)60405-4","volume":"377","author":"PW Noble","year":"2011","unstructured":"Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, et al. Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials. Lancet. 2011;377(9779):1760\u20139.","journal-title":"Lancet"},{"issue":"22","key":"1224_CR13","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","volume":"370","author":"L Richeldi","year":"2014","unstructured":"Richeldi L, Du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071\u201382.","journal-title":"N Engl J Med"},{"issue":"1","key":"1224_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjresp-2018-000397","volume":"6","author":"L Lancaster","year":"2019","unstructured":"Lancaster L, Crestani B, Hernandez P, Inoue Y, Wachtlin D, Loaiza L, et al. Safety and survival data in patients with idiopathic pulmonary fibrosis treated with nintedanib: pooled data from six clinical trials. BMJ Open Respir Res. 2019;6(1):e000397.","journal-title":"BMJ Open Respir Res"},{"issue":"3-b Suppl","key":"1224_CR15","first-page":"S17","volume":"23","author":"M Fisher","year":"2017","unstructured":"Fisher M, Nathan SD, Hill C, Marshall J, Dejonckheere F, Thuresson PO, et al. Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis. J Manag Care Spec Pharm. 2017;23(3-b Suppl):S17\u2013s24.","journal-title":"J Manag Care Spec Pharm"},{"issue":"suppl 62","key":"1224_CR16","first-page":"PA2203","volume":"52","author":"M Vasakova","year":"2018","unstructured":"Vasakova M, Sterclova M, Mogulkoc N, Kus J, M\u00fcller V, Hajkova M, et al. Real world idiopathic pulmonary fibrosis in the EMPIRE registry. Eur Respir J. 2018;52(suppl 62):PA2203.","journal-title":"Eur Respir J"},{"issue":"7","key":"1224_CR17","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1513\/AnnalsATS.201412-553OC","volume":"12","author":"HR Collard","year":"2015","unstructured":"Collard HR, Chen SY, Yeh WS, Li Q, Lee YC, Wang A, et al. Health care utilization and costs of idiopathic pulmonary fibrosis in U.S. Medicare beneficiaries aged 65 years and older. Ann Am Thorac Soc. 2015;12(7):981\u20137.","journal-title":"Ann Am Thorac Soc"},{"issue":"4","key":"1224_CR18","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1164\/rccm.201011-1790OC","volume":"184","author":"RM du Bois","year":"2011","unstructured":"du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, Kartashov A, et al. Ascertainment of individual risk of mortality for patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(4):459\u201366.","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"1224_CR19","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1016\/S2213-2600(15)00093-4","volume":"3","author":"MT Durheim","year":"2015","unstructured":"Durheim MT, Collard HR, Roberts RS, Brown KK, Flaherty KR, King TE Jr, et al. Association of hospital admission and forced vital capacity endpoints with survival in patients with idiopathic pulmonary fibrosis: analysis of a pooled cohort from three clinical trials. Lancet Respir Med. 2015;3(5):388\u201396.","journal-title":"Lancet Respir Med"},{"key":"1224_CR20","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12890-015-0165-1","volume":"16","author":"K Raimundo","year":"2016","unstructured":"Raimundo K, Chang E, Broder MS, Alexander K, Zazzali J, Swigris JJ. Clinical and economic burden of idiopathic pulmonary fibrosis: a retrospective cohort study. BMC Pulm Med. 2016;16:2.","journal-title":"BMC Pulm Med"},{"issue":"12","key":"1224_CR21","doi-asserted-by":"publisher","first-page":"1582","DOI":"10.1016\/j.rmed.2015.11.001","volume":"109","author":"YF Yu","year":"2015","unstructured":"Yu YF, Macaulay DS, Reichmann WM, Wu EQ, Nathan SD. Association of early suspected acute exacerbations of idiopathic pulmonary fibrosis with subsequent clinical outcomes and healthcare resource utilization. Respir Med. 2015;109(12):1582\u20138.","journal-title":"Respir Med"},{"key":"1224_CR22","volume-title":"IBM MarketScan research databases for health services researchers [Internet]","author":"IBM Watson Health","year":"2019","unstructured":"IBM Watson Health. IBM MarketScan research databases for health services researchers [Internet]. Somers: IBM Watson Health; 2019. [updated 2019 Apr; cited 2019 Dec 11]. Available from: https:\/\/www-01.ibm.com\/common\/ssi\/cgi-bin\/ssialias?htmlfid=HPW03041USEN."},{"issue":"6","key":"1224_CR23","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/0895-4356(92)90133-8","volume":"45","author":"RA Deyo","year":"1992","unstructured":"Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol. 1992;45(6):613\u20139.","journal-title":"J Clin Epidemiol"},{"key":"1224_CR24","unstructured":"Bureau of Labor Statistics. Archived consumer price index detailed reports [Internet]. Washington, DC; US Department of Labor; 2018 [updated 2018 Oct 31; cited 2019 Dec 11]. Available from: https:\/\/www.bls.gov\/cpi\/tables\/detailed-reports\/home.htm."},{"key":"1224_CR25","doi-asserted-by":"crossref","unstructured":"Corral M, Reddy S, Chang E, Broder M, Gokhale S, Raimundo K. Rates of Adherence and Persistence of Antifibrotic Therapies in the U.S. Medicare Population. Poster presented at: American Thoracic Society 2019 International Meeting; 2019 May 17\u201322; Dallas, TX.","DOI":"10.1164\/ajrccm-conference.2019.199.1_MeetingAbstracts.A4094"},{"key":"1224_CR26","unstructured":"Lalla D, Bengston L, Raimundo K, Korrer S, Liassou D, Elliott C, et al. Pirfenidone and Nintedanib Compliance and Persistence in a Real World Setting. Poster presented at: American Thoracic Society 2017 International Meeting; 2017 May 19-24; Washington, DC."},{"key":"1224_CR27","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.rmed.2019.06.001","volume":"155","author":"CM Sk\u00f6ld","year":"2019","unstructured":"Sk\u00f6ld CM, Arnheim-Dahlstr\u00f6m L, Bartley K, Janson C, Kirchgaessler K-U, Levine A, et al. Patient journey and treatment patterns in adults with IPF based on health care data in Sweden from 2001 to 2015. Respir Med. 2019;155:72\u20138.","journal-title":"Respir Med"},{"issue":"5","key":"1224_CR28","doi-asserted-by":"publisher","first-page":"829","DOI":"10.3111\/13696998.2012.680553","volume":"15","author":"HR Collard","year":"2012","unstructured":"Collard HR, Ward AJ, Lanes S, Cortney Hayflinger D, Rosenberg DM, Hunsche E. Burden of illness in idiopathic pulmonary fibrosis. J Med Econ. 2012;15(5):829\u201335.","journal-title":"J Med Econ"},{"issue":"4","key":"1224_CR29","first-page":"414","volume":"22","author":"YF Yu","year":"2016","unstructured":"Yu YF, Wu N, Chuang CC, Wang R, Pan X, Benjamin NN, et al. Patterns and economic burden of hospitalizations and exacerbations among patients diagnosed with idiopathic pulmonary fibrosis. J Manag Care Spec Pharm. 2016;22(4):414\u201323.","journal-title":"J Manag Care Spec Pharm"}],"container-title":["BMC Pulmonary Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12890-020-01224-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12890-020-01224-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:05:52Z","timestamp":1625958352000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpulmmed.biomedcentral.com\/articles\/10.1186\/s12890-020-01224-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":29,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1224"],"URL":"https:\/\/doi.org\/10.1186\/s12890-020-01224-5","relation":{},"ISSN":["1471-2466"],"issn-type":[{"value":"1471-2466","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"9 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All study data were accessed with protocols compliant with US patient confidentiality requirements, including the Health Insurance Portability and Accountability Act of 1996 regulations (HIPAA). The databases used in the study are fully de-identified and compliant with the HIPAA. Research using the MarketScan Research Databases falls under Title 45 of the Code of Federal Regulations Part 46.101(b)(4) exemption from Institutional Review Board review because the databases contain only information that cannot be used to identify study subjects. As the data were de-identified, consent from patients was not sought.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"MC is employed by Genentech, Inc. AMK and KD are employed by IBM Watson Health and received funding from Genentech, Inc. to conduct this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"188"}}